During the corresponding time, Arch Therapeutics Inc recorded a revenue increase by 132.55 % year on year, sequentially revenue fell by -2.99 %. While revenue at the Arch Therapeutics Inc 's corporate clients
Arch Therapeutics Inc's Comment on Sales, Marketing and Customers
The company develops and commercializes wound care products for patients and healthcare providers. It utilizes internal and independent sales representatives, distributors, and strategic partners to expand its sales reach. The COVID-19 pandemic has affected the company's commercialization efforts by limiting access to surgeons, strategic partners, and healthcare facilities, particularly outside the United States. Healthcare facilities have rationed staff and resources, reducing focus on wound care, while clinicians have been redirected to urgent COVID-19 needs or required to quarantine. Administrators have faced competing priorities, and elective surgical procedures, including wound interventions, have been periodically constrained. These factors have resulted in a backlog of chronic wounds and increased risks such as infection and amputation. The company identifies these challenges as opportunities for its new technology to address unmet needs in wound care, reflecting systemic issues related to resource constraints and increased demands on clinicians and providers.
Arch Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company develops and commercializes wound care products for patients and healthcare providers. It utilizes internal and independent sales representatives, distributors, and strategic partners to expand its sales reach. The COVID-19 pandemic has affected the company's commercialization efforts by limiting access to surgeons, strategic partners, and healthcare facilities, particularly outside the United States. Healthcare facilities have rationed staff and resources, reducing focus on wound care, while clinicians have been redirected to urgent COVID-19 needs or required to quarantine. Administrators have faced competing priorities, and elective surgical procedures, including wound interventions, have been periodically constrained. These factors have resulted in a backlog of chronic wounds and increased risks such as infection and amputation. The company identifies these challenges as opportunities for its new technology to address unmet needs in wound care, reflecting systemic issues related to resource constraints and increased demands on clinicians and providers.
Sources:
Arch Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Arch Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Arch Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
